Genetics and Genomics of Addiction. Genes (Basel). 2023;14(9)
Genes (Basel). 2023;14(9)
This work was supported by R01DA048890, U01DA043809, P50DA039841 and R01DA059060.
Substance use disorders (SUD), like many neuropsychiatric conditions, are a heteroge- neous group of disorders with similar symptomatology but often different pathoetiology. As diagnosed by the DSM-V, SUD requires at least two of eleven diagnostic criteria, result- ing in the possibility of over 2000 different combinations of symptoms. Further segmenting the disorder is that SUD can involve a variety of legal and illegal substances. There are currently approaches to treating and managing SUD, but we have a limited armamentar- ium. Genetic and genomic studies of addiction can facilitate a more accurate molecular diagnosis and, ultimately, the development of appropriate treatments. Sequenced genomes, new animal model resources, and Genome Wide Association Studies (GWAS) of large sample sizes have made vast inroads into our understanding of the genetics that underlies addiction. Future mechanistic studies will be driven by integrating big data from animal models and human studies to identify their consilient features. This Special Issue, “Genetics and Genomics of Addiction,” focuses on genetic contributions to this disease that may lead to better-targeted therapeutics and diagnostics. This issue contains five original research ar- ticles and one review paper that furthers our collective knowledge of SUD disease etiology and the genetic risk factors underlying the disease.